Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomas
Phase 2
Recruiting
- Conditions
- advanced bone and soft tissue sarcomas
- Registration Number
- JPRN-UMIN000031004
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active double cancers within 5 years(cured intraepithelial carcinoma and intramucosal carcinoma are not included) 2)Cases with complications of severe infection 3)Body temperature more than 38 degree 4)Pregnant or breastfeeding women 5)Severe psychological disease 6) 7)Unstable angina (within 3 months after onset) , myocardial infarction 8)Difficult-to-control hypertension 9)Difficult-to-control diabetes 10)HBs antigen is positive 11)Judgment to attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method objective response rate, disease control rate, incidence rate of adverse event, overall survival